Sepracor Lunesta Launch Delayed By Controlled Substance Scheduling

Sepracor plans for Lunesta to be available within the first quarter of 2005 after the completion of formal Drug Enforcement Agency classification of eszopiclone as a Schedule IV substance. The company originally planned to launch the insomnia agent in early January following FDA approval in December.